	US 11,883,429 B2
	Therapeutic pooled blood apoptotic cell preparations and uses thereof
Dror Mevorach, Jerusalem (IL); and Shai Novik, Ramat Hasharon (IL)
Assigned to Enlivex Therapeutics RDO Ltd, Nes-Ziona (IL)
Filed by Enlivex Therapeutics RDO Ltd, Nes-Ziona (IL)
Filed on Oct. 21, 2020, as Appl. No. 17/075,721.
Application 17/075,721 is a continuation of application No. 15/567,376, granted, now 10,857,181, previously published as PCT/IL2016/050430, filed on Apr. 21, 2016.
Claims priority of provisional application 62/150,305, filed on Apr. 21, 2015.
Prior Publication US 2021/0038644 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/15 (2015.01); A61K 39/00 (2006.01); C12N 5/078 (2010.01); A61K 35/17 (2015.01); A61P 37/00 (2006.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01)

CPC A61K 35/15 (2013.01) [A61K 9/0019 (2013.01); A61K 35/17 (2013.01); A61K 39/0008 (2013.01); A61P 37/00 (2018.01); C12N 5/0634 (2013.01); A61K 2035/122 (2013.01); A61K 2039/515 (2013.01); A61K 2039/58 (2013.01); C12N 2501/39 (2013.01)]

26 Claims

1. A method of prolonging survival of a subject suffering from an immune disease, an autoimmune disease, a cytokine release syndrome (CRS), a cytokine storm, a cancer, or an inflammatory disease, comprising administering to the subject a pharmaceutical composition comprising an irradiated mononuclear-enriched, early apoptotic cell preparation, wherein said early apoptotic cells are irradiated post induction of apoptosis, and wherein said irradiated mononuclear-enriched, early apoptotic cell preparation comprises

a decreased number of non-quiescent non-apoptotic cells;

a suppressed cellular activation of any living non-apoptotic cells; or

a reduced proliferation of any living non-apoptotic cells;

or any combination thereof compared with a preparation comprising a non-irradiated cell population.